Rapid acceleration of diagnostics (radx) tech project #6139: revogene sars-COV-2 assay
Ended Definitive Contract Awarded Last action
- Contract number
- 75N92021C00003
- Awardee
-
Meridian Bioscience Inc. UEI HWJ5BXUMNGK5
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,250,000
Award facts
- Opportunity
-
- 75N92021R0020 Solicitation number
- Rapid Acceleration of Diagnostics (RADx) Tech Project #6139: Revogene SARS-CoV-2 Assay Award Notice · Posted Feb 2, 2021
- Contract value 100% obligated
- $6,250,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Cincinnati, OH 45244, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$1,755,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $2,500,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $5,505,000 |
About this award
This is a $6,250,000.00 firm fixed-price definitive contract awarded by the National Heart Lung and Blood Institute, a civilian agency, to Meridian Bioscience Inc., a foreign-owned, for-profit manufacturer of in vitro diagnostic test kits and medical testing technologies. The contract is for the Rapid Acceleration of Diagnostics (RADx) Tech Project #6139, which involves the supply of Meridian Bioscience's RevogeneⓇ SARS-CoV-2 assay. This diagnostic test is being procured to support the government's efforts to accelerate the development, validation, and commercialization of COVID-19 testing technologies. The contract does not have a small business set-aside designation, indicating that Meridian Bioscience is competing as a large corporate entity. The contract period of performance extends to March 31, 2024.
Quick answers
Who was awarded contract 75N92021C00003?
75N92021C00003 was awarded to Meridian Bioscience Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on February 1, 2021.
How much is contract 75N92021C00003 worth?
The government has obligated $6,250,000 on 75N92021C00003.
Was contract 75N92021C00003 competed?
The extent of competition for 75N92021C00003 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award